EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Unexpected Limited Immune Potentiation of Common Multikinase Inhibitors Combined with Immune Checkpoint Blockade in Hepatocellular Carcinoma: Insights from Murine Models

Ying-Chun Shen, Chia-Lang Hsu, Ching-Ping Yeh, Wan-Ying Lin, Yi-Ting Liu, Ann-Lii Cheng

Liver Cancer · 2026-09-30

DOI: 10.1159/lic/admag016 ↗
AbstractBibliografische Angaben

Abstract

Abstract Introduction Blockade of vascular endothelial growth factor (VEGF) signaling can normalize tumor vasculature and enhance antitumor immunity, as exemplified by atezolizumab plus bevacizumab in hepatocellular carcinoma (HCC). VEGF receptor (VEGFR)-targeting multikinase inhibitors (MKIs) have therefore been considered superior partners for immune checkpoint inhibitors (ICIs) because of their broader inhibition of potentially immune-potentiating kinases. However, most MKI-ICI combinations have shown limited clinical benefit. We hypothesized that MKIs may induce additional biological perturbations beyond VEGFR inhibition that counterbalance immune potentiation. Methods Murine HCC models (Hepa1-6 and Hep53.4) were treated with a selective anti-VEGFR2 antibody (DC101) or VEGFR-targeting MKIs (cabozantinib, lenvatinib, and regorafenib) at low and high doses. Antiangiogenic activity was assessed by CD31+ microvessel density (MVD). Transcriptomic remodeling was analyzed by bulk RNA sequencing with gene set variation analysis and principal component analysis. Tumor-infiltrating lymphocytes were evaluated for proliferation (Ki67 expression) and interferon-γ (IFN-γ) production. Antitumor efficacy with or without anti-PD-1 was assessed in vivo. Results All MKIs demonstrated broadly comparable antiangiogenic activity to DC101 (mean CD31+ MVD reduction vs. control: DC101, 27.6%; MKIs, 23.4–42%). Despite this, selective VEGFR2 blockade induced minimal immune perturbation, whereas MKIs induced divergent transcriptomic remodeling across immune, metabolic, stress-response, and proliferation-related pathways. Notably, low-dose cabozantinib and lenvatinib showed reductions in both immune-activating and immune-suppressive gene signatures, suggesting potentially opposing immunologic effects. Functionally, neither DC101 nor MKIs enhanced proliferation or IFN-γ production of tumor-infiltrating T cells. Moreover, MKIs did not improve the antitumor efficacy of anti-PD-1 therapy. Conclusion Despite similar antiangiogenic effects, MKIs induce broader transcriptomic remodeling without enhancing anti-PD-1 efficacy. These findings suggest that VEGFR-targeting MKIs can induce opposing immune effects beyond VEGF-VEGFR blockade, potentially limiting net enhancement of antitumor immunity.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →